Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors

被引:157
作者
Zohar, J [2 ]
Westenberg, HGM
机构
[1] Acad Ziekenhuis Utrecht, Div Psychiat, Utrecht, Netherlands
[2] Tel Aviv Univ, Herzliyya, Israel
关键词
SSRI; TCA; anxiety disorder;
D O I
10.1111/j.1600-0447.2000.tb10947.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Anxiety disorders are the most common mental health disorders. While the older tricylic antidepressants (TCAs) al-e efficacious in the treatment of many anxiety disorders, recent studies with fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) have emphasized the role of serotonin in the aetiology of these conditions. Method: We reviewed the efficacy, safety and tolerability of TCAs and SSRIs in the treatment of the most common anxiety disorders, specifically, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social phobia and generalized anxiety disorder. Results: Both the TCA and SSRI antidepressants are effective in treating a wide variety of anxiety disorders. SSRIs, due to their greater safety and tolerability, should be the preferred choices in treating anxiety disorders in those instances where TCAs and SSRIs are considered equally effective. In the cases of OCD and social phobia, SSRIs are almost always preferable given that the TCAs do not appear effective in these disorders. Conclusion: Further research is needed on the naturalistic long-term use of the TCAs and SSRIs in the treatment of anxiety disorders.
引用
收藏
页码:39 / 49
页数:11
相关论文
共 121 条
  • [1] AGUIAR LM, 1998, ANN M AM PSYCH ASS T
  • [2] Allgulander C, 1998, PSYCHOPHARMACOL BULL, V34, P165
  • [3] DOUBLE-BLIND COMPARATIVE-STUDY OF CLOMIPRAMINE AND AMITRIPTYLINE IN OBSESSIVE NEUROSIS
    ANATH, J
    PECKNOLD, JC
    VANDENSTEEN, N
    ENGELSMANN, F
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1981, 5 (03): : 257 - 262
  • [4] Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder
    Ballenger, JC
    Wheadon, DE
    Steiner, M
    Bushnell, W
    Gergel, IP
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (01) : 36 - 42
  • [5] A risk-benefit assessment of pharmacological treatments for panic disorder
    Bennett, JA
    Moioffer, M
    Stanton, SP
    Dwight, M
    Keek, PE
    [J]. DRUG SAFETY, 1998, 18 (06) : 419 - 430
  • [6] BLACK DW, 1993, ARCH GEN PSYCHIAT, V50, P44
  • [7] Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia
    Bouwer, C
    Stein, DJ
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1998, 49 (01) : 79 - 82
  • [8] SEROTONIN UPTAKE INHIBITORS ARE SUPERIOR TO IMIPRAMINE AND ALPRAZOLAM IN ALLEVIATING PANIC ATTACKS - A METAANALYSIS
    BOYER, W
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (01) : 45 - 49
  • [9] BRADY KT, 1995, J CLIN PSYCHIAT, V56, P502
  • [10] A PRACTICAL UPDATE ON ANXIETY DISORDERS AND THEIR PHARMACOLOGICAL TREATMENT
    BROWN, CS
    RAKEL, RE
    WELLS, BG
    DOWNS, JM
    AKISKAL, HS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) : 873 - 884